Persistent generalized anxiety after brief exposure to the dopamine antagonist metoclopramide

Psychiatry and Clinical Neurosciences

Volumn 61, Issue 2, 2007, Pages 193-195

  Kluge, Michael ^a,b   Schüssler, Petra ^a   Steiger, Axel ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b NONE   (Germany)

Author keywords

Anxiety; Dopamine; Dopaminergic; Generalized anxiety disorder

Indexed keywords

BIPERIDEN; LORAZEPAM; METOCLOPRAMIDE; MIRTAZAPINE;

ADULT; AGITATION; ARTICLE; CASE REPORT; CONCENTRATION LOSS; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DOPAMINERGIC TRANSMISSION; DRUG EXPOSURE; DYSPNEA; DYSTONIA; EPIGASTRIC DISCOMFORT; FEMALE; GENERALIZED ANXIETY DISORDER; HEART PALPITATION; HUMAN; NAUSEA; NEUROPATHOLOGY; NEUROTOXICITY; PANIC; POLYDIPSIA; POLYURIA; PROVOCATION TEST; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SWEATING; THIRST; XEROSTOMIA;

ADULT; AGORAPHOBIA; ANTIEMETICS; DOPAMINE ANTAGONISTS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; METOCLOPRAMIDE; NAUSEA; PANIC DISORDER; PSYCHIATRIC STATUS RATING SCALES;

EID: 33847689426     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2007.01637.x     Document Type: Article

References (26)

1. Cancela LM, Basso AM, Martijena ID, Capriles NR, Molina VA. A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: A behavioral and neurochemical study. Brain Res. 2001; 909: 179-186.
2. Millan MJ, Brocco M, Papp M et al. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors. III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole. J. Pharmacol. Exp. Ther. 2004; 309: 936-950.
3. Steiner H, Fuchs S, Accili D. D3 dopamine receptor-deficient mouse: Evidence for reduced anxiety. Physiol. Behav. 1997; 63: 137-141.
4. Mizuki Y, Suetsugi M, Ushijima I, Yamada M. Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry 1997; 21: 573-590.
5. Stein DJ, Westenberg HG, Liebowitz MR. Social anxiety disorder and generalized anxiety disorder: Serotonergic and dopaminergic neurocircuitry. J. Clin. Psychiatry 2002; 63 (Suppl. 6): 12-19.
6. Schneier FR, Liebowitz MR, Abi-Dargham A et al. Low dopamine D (2) receptor binding potential in social phobia. Am. J. Psychiatry 2000; 157: 457-459.
7. Gu SF. A double-blind study of metoclopramide in the treatment of schizophrenia and determination of prolactin. Zhonghua Shen Jing Jing Shen Ke Za Zhi 1992; 25: 328-330 (in Chinese).
8. Anfinson TJ. Akathisia, panic, agoraphobia, and major depression following brief exposure to metoclopramide. Psychopharmacol. Bull. 2002; 36: 82-93.
9. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva, 1992.
10. Rickels K, Rynn MA. What is generalized anxiety disorder? J. Clin. Psychiatry 2001; 62 (Suppl. 11): 4-12.
11. Tsukamoto T, Asakura M, Tsuneizumi T, Satoh Y, Shinozuka T, Hasegawa K. Therapeutic effects and side effects in patients with major depression treated with sulpiride once a day. Prog. Neuropsychopharmacol. Biol. Psychiatry 1994; 18: 615-618.
12. Cassano GB, Jori MC, AMIMAJOR Group. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression:A randomized, double-blind, parallel group study. Int. Clin. Psychopharmacol. 2002; 17: 27-32.
13. Racagni G, Canonico PL, Ravizza L, Pani L, Amore M. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology 2004; 50: 134-143.
14. Kato K. Response of patients in mixed state of anxiety and depression to low dose sulpiride. Igaku Kenkyu 1993; 63: 15-19.
15. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-852.
16. Lin CH, Hsieh CC, Chen SJ, Wu TC, Chung RL, Tang RB. The diagnostic value of serum interleukins 6 and 8 in children with acute gastroenteritis. J. Pediatr. Gastroenterol. Nutr. 2006; 43: 25-29.
17. Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: Stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005; 135: 659-678.
18. Maes M, Song C, Lin A et al. The effects of psychological stress on humans: Increased production of proinflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313-318.
19. Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov. Disord. 2005; 20: 86-89.
20. Hayase T, Yamamoto Y, Yamamoto K. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: Interactions with endogenous cannabinoid receptor ligands. Behav. Pharmacol. 2005; 16: 395-404.
21. Stein DJ. Comorbidity in generalized anxiety disorder: Impact and implications. J. Clin. Psychiatry 2001; 62 (Suppl. 11): 29-34.
22. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSMIII-R Generalized anxiety disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 2004; 51: 355-364.
23. Mennin DS, Heimberg RG, Jack MS. Comorbid generalized anxiety disorder in primary social phobia: Symptom severity, functional impairment, and treatment response. J. Anxiety Disord. 2000; 14: 325-343.
24. Nakayama K, Sakurai T, Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain. Res. Bull. 2004; 63: 237-241.
25. Devoto P, Flore G, Pira L, Longu G, Gessa GL. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur. J. Pharmacol. 2004; 487: 105-111.
26. Millan MJ, Gobert A, Rivet JM et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: A comparison with citalopram. Eur. J. Neurosci. 2000; 12: 1079-1095.